Pioglitazone initiation and subsequent hospitalization for congestive heart failure.
about
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic reviewThe risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studiesPharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia.Diffusion patterns of new anti-diabetic drugs into hospitals in Taiwan: the case of thiazolidinediones for diabetes.Molecular determinants of the cardiometabolic phenotype.Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality.PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.Practical application of nonrandomized research to patient care: a case study of nesiritide.Neighborhood deprivation and change in BMI among adults with type 2 diabetes: the Diabetes Study of Northern California (DISTANCE).PPARgamma agonists: safety issues in heart failure.Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?Diabetes, left ventricular systolic dysfunction, and chronic heart failure.Thiazolidinediones in type 2 diabetes: a cardiology perspective.Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort studyNew prescription medication gaps: a comprehensive measure of adherence to new prescriptions.Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations.The Low-Dose (7.5 mg/day) Pioglitazone Therapy.Differential effects of pioglitazone on metabolic parameters in newly diagnosed, drug-naïve Japanese patients with type 2 diabetes with or without metabolic syndrome.Effects of low-dose pioglitazone on glucose control, lipid profiles, renin-angiotensin-aldosterone system and natriuretic peptides in diabetic patients with coronary artery disease.Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes.The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy.Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus.Comorbidities in Heart Failure.Residual effect of reductions in red blood cell count and haematocrit and haemoglobin levels after 10-month withdrawal of pioglitazone in patients with Type 2 diabetes.
P2860
Q22242077-B0277DBE-10CB-4503-93E2-1B8E4DEC2028Q26999933-04C2B50B-2A93-44B4-983B-38919CA9C4BAQ30250020-ED95C45F-AA47-4E07-9819-FB45DE7DE59BQ33807810-50B51433-D11B-4AFC-9017-4F043EA6D228Q33921392-D1E4660F-B453-442F-8322-961D8E1B5B64Q34099031-69916A22-2F3E-434B-9835-F32836E509C4Q34499287-AFE9DC14-3F4C-49C8-A4BE-3C16D9B0C8FDQ36407383-079D997C-06CD-47A2-926C-C37C06237FCDQ36536316-06D779C0-A25D-4FC8-A7DE-1457F4055BCEQ36569766-784C6BBE-8886-410C-84B4-8C497F88A005Q36693881-C8CF4893-E44E-4C55-B521-1377811642C0Q36782667-77364AED-0DF3-432F-91EA-D2E9341DD8B8Q36857537-3D994AE1-DD7F-4CC6-AB06-2A3547902FC5Q37107490-81AC0281-CA91-4139-A7DE-6D97DF65790BQ37143034-AF058CE5-38E9-4912-AC8D-DA4E54C81156Q37242253-89E9B083-B565-4097-B36D-8E9E102F0ABFQ37310162-C5E8E9F3-7AFD-443E-8311-7579ED8814FAQ37368835-1EA2EF82-8CA0-4D60-AE5D-5148583E27D6Q38248399-AA369322-A0FD-4BBA-8C07-0FF1D721DDA0Q41353986-5D95FAD5-1B31-4E3D-93FF-954E897E38AEQ42936496-F7F18623-6E82-4DC1-B6B9-6B13CC655A53Q44311462-92E2E3B1-B7AF-450A-A29D-75FE2D0243ABQ45330821-7290EAA2-A405-4A7C-9228-C7CE7C9510B5Q46525578-D09C722F-E889-4485-A091-DEAA21556C8CQ46743528-2A947289-BDF5-4E11-B757-2011386CA3D7Q47744924-AC277471-65EE-4134-83BD-9EB8A3393746Q50472209-5D71A198-C664-44F7-806E-E38A6DF0FC8C
P2860
Pioglitazone initiation and subsequent hospitalization for congestive heart failure.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Pioglitazone initiation and subsequent hospitalization for congestive heart failure.
@ast
Pioglitazone initiation and subsequent hospitalization for congestive heart failure.
@en
type
label
Pioglitazone initiation and subsequent hospitalization for congestive heart failure.
@ast
Pioglitazone initiation and subsequent hospitalization for congestive heart failure.
@en
prefLabel
Pioglitazone initiation and subsequent hospitalization for congestive heart failure.
@ast
Pioglitazone initiation and subsequent hospitalization for congestive heart failure.
@en
P2093
P2860
P1433
P1476
Pioglitazone initiation and subsequent hospitalization for congestive heart failure.
@en
P2093
P2860
P304
P356
10.1111/J.1464-5491.2005.01704.X
P577
2005-08-01T00:00:00Z